AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer

AEON Biopharma, Inc.

On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.
Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025.
Ms. Sy previously served as VP, Corporate Controller since August 2023; base salary increased to $275,000 from $245,000.
Mr. Fischer continues as Chairman of the Board; no other compensation changes disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Sy

Chief Accounting Officer and principal financial officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-04
Filed: April 8, 2025, 7:59 PM ET

On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.

Appointed (interim)

Jost Fischer

Interim President, Chief Executive Officer and principal executive officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-04
Filed: April 8, 2025, 7:59 PM ET

On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jennifer Sy was appointed as Chief Accounting Officer and principal financial officer at AEON Biopharma, Inc..

Action: appointed
Role: Chief Accounting Officer and principal financial officer

Exact text from the filing

On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jost Fischer was appointed as Interim President, Chief Executive Officer and principal executive officer at AEON Biopharma, Inc..

Action: appointed
Role: Interim President, Chief Executive Officer and principal executive officer

Exact text from the filing

On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.

View on SEC.gov

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.